Mirador Therapeutics · 1 day ago
Scientist, Translational Genomics - San Diego, CA
San Diego, CA
Full-time
Onsite
Mid, Senior Level
$120K/yr - $175K/yr
3+ years expMirador Therapeutics, Inc. is a clinical-stage precision medicine company focused on developing next-generation therapeutics for immunology and inflammation. The role involves integrating and analyzing multi-omics data to support drug development and clinical trials in immunology and inflammation.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Design and execute genomic studies to uncover causal mechanisms underlying immune-mediated and inflammatory diseases by integrating multi-omics data from both public and proprietary sources
Collaborate with the Immunology team and the broader R&D organization to provide data-driven guidance on study design, drug target validation, combination target nomination, and indication expansion for clinical assets
Utilize genomic markers to predict treatment responses and stratify patient subpopulations through network and pathway analyses integrating multi-omics datasets and preclinical or clinical efficacy data
Partner with internal teams (Immunology, AI) and external collaborators (academic and industry) to collect functional data and develop systems biology and machine learning approaches that accelerate drug discovery and development
Contribute to and oversee translational study plans, author scientific reports, and present methods, findings, and conclusions to a publication-ready standard
Communicate analysis strategies and scientific insights to members of cross-functional teams—including biologists, clinicians, and leadership—to inform research and development decisions
Qualification
Required
Ph.D. in Computational Biology, Bioinformatics, Computer Science, Engineering, Statistics, or related discipline is required
3 or more years of post-graduation or biotech and/or pharmaceutical industry experience is required
2 or more years of relevant biotech and/or pharmaceutical industry experience in a related field
Proficiency in at least one high-level programming language (e.g., R, Python, or C/C++) with demonstrated experience in complex data analysis and reproducible research practices
Expertise in multi-omics data integration, including genetics, bulk RNA-seq, and single-cell RNA-seq, to identify genomic signatures underlying disease mechanisms and therapeutic responses
Recognized as a subject matter expert (SME) in statistical genetics, GWAS/QTL integration, causal inference/discovery, or polygenic risk modeling, with a solid understanding of machine learning and systems biology
Proven track record of contributing to and advancing cross-functional, multi-disciplinary research projects
Excellent interpersonal and communication skills, with the ability to distill complex scientific data into clear, actionable insights that support strategic decision-making
Strong work ethic and proactive problem-solving mindset, fostering effective scientific collaboration and driving projects toward successful outcomes
Thrives in dynamic, fast-paced, and collaborative environments, working effectively with diverse teams across disciplines
Preferred
Background in inflammatory or autoimmune diseases, and experience in translational research, including biomarker data analysis for clinical trials, are highly desirable
Benefits
Bonus
Equity
Comprehensive benefits
Company
Mirador Therapeutics
Mirador Therapeutics develops precision medicines for immune-mediated diseases.
11-50 employees
H1B Sponsorship
Mirador Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
Funding
Current Stage
Growth StageTotal Funding
$730MKey Investors
ARCH Venture Partners
2026-01-12Series B· $250M
2024-04-03Series Unknown· $80M
2024-03-21Series A· $400M
Recent News
2026-01-16
Company data provided by crunchbase